Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer

Front Cover
Mohammad Resa Nowrousian
Springer Science & Business Media, Dec 19, 2007 - Medical - 866 pages
Anemia is a frequent complication of cancer and its treatment. It produces many symptoms and significantly impairs metabolic and physiologic functions as well as patients' activity, well-being and quality of life. Life expectancy is also affected. This book, now being published in its second edition, comprehensively presents the current knowledge on anemia in cancer and its treatment with rhEPO. Future developments are also discussed. Based on updated and new chapters, including a broader spectrum of topics, outstanding international experts describe the scientific and clinical aspects of anemia in various fields of oncology and give diagnostic and therapeutic recommendations on when and how to use rhEPO. The book, considered as a standard work, will again serve as an essential source of information for radiotherapists, medical oncologists, hematologists, internists, pediatricians, surgeons, specialists in transfusion and laboratory medicine, and pharmacologists.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

Physiology of erythropoiesis
1
Biology of EPO and EPOreceptor
67
The role of erythropoietin receptor expression on tumor cells
81
Problems associated with erythropoietin receptor determination on tumor cells
103
Definition classification and characterization of anemia in cancer
117
Pathophysiology of anemia in cancer
149
Prevalence and incidence of anemia and risk factors for anemia in patients with cancer
189
Significance of anemia in cancer chemotherapy
207
Recombinant human erythropoietin rhEPO therapy in myelodysplasia
531
Prediction of response to rhEPO in the anemia of cancer
541
rhEPO in hematopoietic stem cell transplantation
583
Treatment of anemia with rhEPO in radiation oncology
615
Recombinant human erythropoietin in pediatric oncology
635
rhEPO in surgical oncology
663
Erythropoiesis iron metabolism and iron supplementation during erythropoietin therapy
679
Are there risks for use of iron in cancer patients?
703

Incidence and impact of anemia in radiation oncology
249
Relationship between hemoglobin levels and tumor oxygenation
265
Tumor hypoxia and therapeutic resistance
283
Symptoms of anemia
307
Impact of anemia and red blood cell transfusion on organ function
317
Relationship of hemoglobin fatigue and quality of life in anemic cancer patients
369
When to use red blood cell transfusions in cancer patients with solid tumours?
393
Pharmacology pharmacokinetics and safety of recombinant human erythropoietin preparations
407
Epoetin treatment of anemia associated with multiple myeloma and nonHodgkins lymphoma
433
rhEPO in anemic patients with solid tumors and chemotherapy efficacy and safety
449
Early intervention with recombinant human erythropoietin for chemotherapyinduced anemia
509
Metabolic and physiologic effects of rhEPO in anemic cancer patients
713
Effects of rhEPO on quality of life in anemic cancer patients
729
Thrombosis during therapy with erythropoiesis stimulating agents in cancer
745
The effect of rhEPO on survival in anemic cancer patients
759
From bench to bedside Neuroprotective effects of erythropoietin
771
rhEPO in patients with anemia and congestive heart failure
793
Costeffectiveness of treating cancer anaemia
813
Addendum
851
Index
853
Copyright

Other editions - View all

Common terms and phrases

Bibliographic information